Core Insights - MAIA Biotechnology, Inc. has reported promising overall survival results for patients treated with ateganosine in its Phase 2 THIO-101 clinical trial for non-small cell lung cancer (NSCLC) [2][4] Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine, a first-in-class telomere-targeting agent [8] - The company aims to improve and extend the lives of cancer patients through innovative therapies [8] Clinical Trial Highlights - In the ongoing Phase 2 THIO-101 trial, eight patients have shown overall survival beyond two years without subsequent lines of therapy [2] - The trial has treated a total of 79 patients in Parts A and B, with Part C currently enrolling up to 48 participants in Asia and Europe [2][5] - The treatment regimen of ateganosine followed by cemiplimab has demonstrated an acceptable safety profile in a heavily pre-treated population [2][7] Mechanism of Action - Ateganosine works by targeting telomeres, which are crucial for cancer cell survival and resistance to therapies, leading to selective cancer cell death [4] - The drug induces immune responses that may enhance the effectiveness of subsequent treatments with PD-(L)1 inhibitors [4] Survival Data - One patient in third-line therapy achieved survival of 33 months, while four patients in second-line therapy had survival exceeding 30 months [6] - The expected survival for heavily pre-treated patients is significantly lower, at 5.8 months for standard treatments [6]

Table of Contents As filed with the U.S. Securities and Exchange Commission on June 8, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 83-1495913 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No. ...

As filed with the U.S. Securities and Exchange Commission on April 21, 2023. Registration No. 333-269606 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 3) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) Classification Code Number) 444 West Lake Stree ...

As filed with the U.S. Securities and Exchange Commission on April 4, 2023. Registration No. 333-269606 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...

As filed with the U.S. Securities and Exchange Commission on February 6, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial (I.R.S. Employer Identification No.) Classification Code Number) 444 West Lak ...